Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
1847 Goedeker (GOED)
PaxMedica (PXMD)
Vistas Media Acquisition (VMACU)
Yucaipa Acquisition (YAC.U)
Rackspace Technology, Inc. (RXT)
GO Acquisition (GOAC.U)
BigCommerce Holdings, Inc (BIGC)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Priced IPO
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
Pandion Therapeutics, Inc. (PAND)
ALX Oncology Holdings Inc. (ALXO)
Trean Insurance Group, Inc. (TIG)
Relay Therapeutics, Inc. (RLAY)
GoHealth, Inc. (GOCO)
More companies

Annovis Bio (ANVS)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

Annovis is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease in Down syndrome (AD-DS), Alzheimer's disease (AD) and Parkinson's disease (PD). They have an ongoing Phase 2a proof-of-concept study in AD patients and have planned to commence a second Phase 2a study in PD patients. They are developing their lead compound, ANVS-401, for chronic neurodegenerative diseases, such as AD-DS, AD and PD. In a number of studies, ANVS-401 inhibited the synthesis of neurotoxic proteins—APP/Ab (APP), tau/phospho-tau (tau) and a-Synuclein (a-SYN)—that are the main cause of neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. When that communication is impaired, the immune system is activated and attacks the nerve cells, eventually killing them. Through their patented product platform, in clinical studies in mildly cognitive impaired (MCI) patients, ANVS-401 normalized levels of neurotoxic proteins and inflammatory factors. In preclinical studies, the lowering of neurotoxic proteins also led to the restoration of axonal transport, lowering of inflammation and prevention of nerve cell death.
Industry
PHARMACEUTICAL PREPARATIONS
CEO CFO
Maria Maccecchini Jeffrey McGroarty
Employees Founded
2 2008

Contacts

Address: 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312, US

Telephone: (610) 727-3913

Web page: http://www.annovisbio.com

IPO information

Expected Date 1/29/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $41.5
Revenues (MM) $0
Net Income (Loss) (MM) $-0.95

Voting

What do you think will happen with the ANVS share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 1.4
Shares Revised (MM) 0
Expected offer amount (MM) $10
Realized offer amount(MM) $0
Underwriters
ThinkEquity (a division of Fordham Financial Management, Inc. )
CO-Managers
-

Sector: Healthcare

Tweets about $ANVS

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats